Huntington Disease Clinical Trial
— MtIOfficial title:
Move to Improve: Telehealth Exercise and Music Intervention for Individuals With Huntington's Disease
The purpose of this study is to determine if a movement to music exercise program delivered via telehealth is feasible and safe for individuals with neurodegenerative disease and their caregivers (Aim 1). A secondary aim will be to determine if a movement to music exercise program delivered via telehealth improves balance, cognition, mobility, and quality of life (Aim 2).
Status | Recruiting |
Enrollment | 60 |
Est. completion date | December 2024 |
Est. primary completion date | December 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 21 Years and older |
Eligibility | Inclusion Criteria: - confirmed diagnosis of a degenerative neurologic disorder such as HD, PD, mild dementia or mild cognitive impairment - above the age of 21 years - has a care partner who can assist with the program. - able to access the online exercise program - able to understand study and provide consent. - stable medication regime for four weeks prior to initiation of trial, and anticipated to be able to maintain a stable regime for the course of trial - OR regularly assisting in the care for an individual that meet the above criteria (for care partners) Exclusion Criteria: - any physical or psychiatric condition that would prohibit the participant from completing the intervention or the full battery of assessments - unable to understand or communicate in spoken English - currently involved in any intervention trial or within four weeks of completing an intervention trial - current, regular participation in a structured exercise program three times per week or more |
Country | Name | City | State |
---|---|---|---|
United States | The Ohio State University | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
Ohio State University | Huntington's Disease Society of America |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Open-ended questionnaire | A survey to describe participant perceptions about the intervention at the end of the study | 12 weeks | |
Primary | Change in 4 stage balance test from baseline: feet together from baseline | How long a participant can stand with feet together up to 10 seconds | 12 weeks | |
Primary | Change in 4 stage balance test from baseline: feet together from baseline - TELEHEALTH | How long a participant can stand with feet together up to 10 seconds collected via telehealth | 12 weeks | |
Primary | Change in 4 stage balance test from baseline: feet staggered from baseline | How long a participant can stand with feet staggered up to 10 seconds | 12 weeks | |
Primary | Change in 4 stage balance test from baseline: feet staggered from baseline - TELEHEALTH | How long a participant can stand with feet staggered up to 10 seconds collected via telehealth | 12 weeks | |
Primary | Change in 4 stage balance test from baseline: feet in tandem from baseline | How long a participant can stand with feet heel to toe up to 10 seconds | 12 weeks | |
Primary | Change in 4 stage balance test from baseline: feet in tandem from baseline - TELEHEALTH | How long a participant can stand with feet heel to toe up to 10 seconds collected via telehealth | 12 weeks | |
Primary | Change in 4 stage balance test from baseline: single leg stance from baseline | How long a participant can stand on one foot to toe up to 60 seconds | 12 weeks | |
Primary | Change in 4 stage balance test from baseline: single leg stance from baseline - TELEHEALTH | How long a participant can stand on one foot to toe up to 60 seconds collected via telehealth | 12 weeks | |
Primary | Change in 5 Times Sit to Stand Test from baseline | How long a participant can stand up and sit down from a standard chair with arms crossed across chest in seconds | 12 weeks | |
Primary | Change in 5 Times Sit to Stand Test from baseline - TELEHEALTH | How long a participant can stand up and sit down from a standard chair with arms crossed across chest in seconds collected via telehealth | 12 weeks | |
Primary | Change in Adapted Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Questionnaire from baseline | A patient-reported outcome measure that assesses perceived difficulty in completing physical tasks. | 12 weeks | |
Primary | Change in Patient Health Questionnaire (PHQ-9) from baseline | A self-administered instrument for depression module, which scores each of the items as "0" (not at all) to "3" (nearly every day), with higher scores indicating worse depression | 12 weeks | |
Primary | Change in Patient Health Questionnaire (PHQ-9) from baseline - TELEHEALTH | A self-administered instrument for depression module, which scores each of the items as "0" (not at all) to "3" (nearly every day), with higher scores indicating worse depression. Collected via telehealth | 12 weeks | |
Primary | Change in 12-item Self-Report World Health Organization Disability Assessment Schedule (WHODAS) 2.0 questionnaire from baseline | A patient reported outcome measure containing 12 items that the participant rates his or her difficulties in maintaining personal care, occupational tasks and functioning in relation to family and society with a score range from 12 to 60, where higher scores indicate higher disability or loss of function. | 12 weeks | |
Primary | Change in 12-item Self-Report World Health Organization Disability Assessment Schedule (WHODAS) 2.0 questionnaire from baseline - TELEHEALTH | A patient reported outcome measure containing 12 items that the participant rates his or her difficulties in maintaining personal care, occupational tasks and functioning in relation to family and society with a score range from 12 to 60, where higher scores indicate higher disability or loss of function. Collected via telehealth | 12 weeks | |
Primary | Change in verbal fluency from baseline | A measure of cognition that involves asking the participant to name as many animals as they can in 60 seconds and then they are given a letter and asked to name all of the words that begin with that letter in 60 seconds. The more words the better the outcome. | 12 weeks | |
Primary | Change in verbal fluency from baseline - TELEHEALTH | A measure of cognition that involves asking the participant to name as many animals as they can in 60 seconds and then they are given a letter and asked to name all of the words that begin with that letter in 60 seconds. The more words the better the outcome. Collected via telehealth. | 12 weeks | |
Primary | Change in Digit Span test from baseline | A measure of cognition that involves asking the participant to recall a series of numbers. The more numbers recalled accurately the better the outcome. | 12 weeks | |
Primary | Change in Digit Span test from baseline - TELEHEALTH | A measure of cognition that involves asking the participant to recall a series of numbers. The more numbers recalled accurately the better the outcome. Collected via telehealth | 12 weeks | |
Secondary | Change in Unified Huntington's Disease Rating Scale (UHDRS) Motor Scale from baseline | UHDRS Motor Scale is administered by a trained rater who has the individual perform tasks such as tapping fingers and standing up and walking. The rater then scores performance on a scale of 0-4. Higher scores indicates worse outcomes | 12 weeks | |
Secondary | Change in Unified Huntington's Disease Rating Scale (UHDRS) Functional Assessment scale from baseline | A questionnaire that participants fill out rating their difficulty dealing with life situations on a yes or no scale | 12 weeks | |
Secondary | Change in Unified Huntington's Disease Rating Scale (UHDRS) Independence scale from baseline | A questionnaire that participants fill out rating their difficulty performing tasks on a scale of 10-100 with 100 indicating independence | 12 weeks | |
Secondary | Change in Symbol Digit Modality Test (SDMT) from baseline | The SDMT is a part of the standard cognitive battery used with Huntington's disease that involves a simple substitution task, using a reference key, the examinee has 90 seconds to pair specific numbers with given geometric figures. | 12 weeks | |
Secondary | Change in the Stroop interference test from baseline | The Stroop is a part of the standard cognitive battery used with Huntington's disease that involves participants to read three different tables as fast as possible. Two of them represent the "congruous condition" in which participants are required to read names of colors (henceforth referred to as color-words) printed in black ink (W) and name different color patches (C). Conversely, in the third table, named color-word (CW) condition, color-words are printed in an inconsistent color ink (for instance the word "red" is printed in green ink). | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Not yet recruiting |
NCT04429230 -
Non-invasive Brain Stimulation in Huntington's Disease
|
N/A | |
Recruiting |
NCT05032196 -
Study of WVE-003 in Patients With Huntington's Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT03599076 -
Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease
|
||
Terminated |
NCT04617860 -
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT05748288 -
Development of the Virtual Unified Huntington's Disease Rating Scale
|
||
Not yet recruiting |
NCT05360082 -
Comparison Between [11C]UCB-J and [18F]SynVest-1 PET in HD.
|
||
Not yet recruiting |
NCT04370470 -
Development of Assessments for Later Stage HD
|
||
Recruiting |
NCT01834053 -
Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea.
|
Phase 1/Phase 2 | |
Completed |
NCT01458470 -
A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease
|
Phase 2 | |
Completed |
NCT01357681 -
Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)
|
Phase 2 | |
Completed |
NCT00980694 -
Bioavailability of Ubiquinol in Huntington Disease
|
Phase 1 | |
Completed |
NCT00146211 -
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease
|
Phase 3 | |
Recruiting |
NCT01412125 -
Study of Biomarkers That Predict the Evolution of Huntington's Disease
|
N/A | |
Completed |
NCT00075140 -
Family Health After Predictive Huntington Disease (HD) Testing
|
Phase 3 | |
Recruiting |
NCT04818060 -
Preparing for Prevention of Huntington's Disease (PREVENT-HD)
|
||
Active, not recruiting |
NCT04698551 -
NIPD on cffDNA for Triplet Repeat Diseases
|
||
Not yet recruiting |
NCT04301726 -
Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HD
|
Phase 1 | |
Completed |
NCT03421327 -
Genetic Risk: Whether, When, and How to Tell Adolescents
|
||
Recruiting |
NCT03296176 -
Metabolomic Study in Huntington's Disease (METABO-HD)
|
N/A |